CeriBell, Inc.
NASDAQ:CBLL · NASDAQ Global Select
+$0.25 today
Vol 0.70M · Avg 0.29M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CBLL · Revenue to Net Income
Key Ratios
Analysis
$95.1M of revenue converted into -$60.4M of net income for the selected period. Gross margin is 87.8% and net margin is -63.3%, showing how much revenue survives after costs and taxes. EPS is $-1.63, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $89.1M +36.1% | $65.4M +44.7% | $45.2M +74.5% | $25.9M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $10.8M +24.1% | $8.7M +23.1% | $7.1M +59.4% | $4.4M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $78.3M +37.9% | $56.8M +48.7% | $38.2M +77.6% | $21.5M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 87.9% +1.2pp | 86.7% +2.3pp | 84.4% +1.5pp | 82.9% | 45.5% | 9.8% | 28.9% |
| Research & Development | $19.1M +41.2% | $13.6M +50.8% | $9.0M +24.2% | $7.2M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $117.5M +41.8% | $82.9M +40.0% | $59.2M +17.8% | $50.3M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $136.7M +41.7% | $96.5M +41.4% | $68.2M +18.6% | $57.5M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $1.3M +17.5% | $1.1M +34.7% | $847.0K +70.4% | $497.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$50.2M -34.5% | -$37.3M -40.8% | -$26.5M +24.4% | -$35.1M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | -56.3% +0.7pp | -57.0% +1.6pp | -58.6% +76.6pp | -135.3% | 10.0% | 5.6% | 46.3% |
| Operating Income | -$58.4M -47.1% | -$39.7M -32.2% | -$30.0M +16.6% | -$36.0M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -65.6% -4.9pp | -60.7% +5.7pp | -66.4% +72.5pp | -139.0% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 | $0 | $0 | $0 | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $1.9M -5.1% | $2.0M -5.1% | $2.1M +30.9% | $1.6M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $5.0M +768.9% | -$746.0K -226.9% | $588.0K +151.5% | -$1.1M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$53.4M -32.0% | -$40.5M -37.4% | -$29.5M +20.7% | -$37.2M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -60.0% +1.8pp | -61.8% +3.3pp | -65.1% +78.2pp | -143.4% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $0 | $0 -100.0% | $11.0K +450.0% | $2.0K | $666.8M | $1.3B | -$1.6B |
| Net Income | -$53.4M -32.0% | -$40.5M -37.3% | -$29.5M +20.7% | -$37.2M | $5.0B | $4.9B | $4.8B |
| Net Margin | -60.0% +1.8pp | -61.8% +3.3pp | -65.1% +78.2pp | -143.4% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$1 +56.9% | -$3 -169.0% | -$1 +20.8% | -$2 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$1 +56.9% | -$3 -169.0% | -$1 +20.8% | -$2 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $36.5M +205.8% | $11.9M -48.8% | $23.3M +0.0% | $23.3M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $36.5M +205.8% | $11.9M -48.8% | $23.3M +0.0% | $23.3M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.91B
Enhabit, Inc.
EHAB
$706.91M
Surmodics, Inc.
SRDX
$614.51M
OrthoPediatrics Corp.
NASDAQ:KIDS
$472.09M
Varex Imaging Corporation
NASDAQ:VREX
$439.90M
Autolus Therapeutics plc
NASDAQ:AUTL
$408.53M
Standard BioTools Inc.
NASDAQ:LAB
$311.94M
Semler Scientific, Inc.
SMLR
$310.75M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$264.36M
Quantum-Si incorporated
NASDAQ:QSI
$191.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CBLL generate?
CeriBell, Inc. (CBLL) reported $89.06M of revenue in fiscal 2025.
Is CBLL profitable?
CeriBell, Inc. (CBLL) reported -$53,412,000.00 of net income, with a net margin of -60.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.